Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients

Francesca Collina, Margherita Cerrone, Valentina Peluso, Michelino de Laurentiis, Roberta Caputo, Rossella De Cecio, Giuseppina Liguori, Gerardo Botti, Monica Cantile, Maurizio Di Bonito

Research output: Contribution to journalArticle

Abstract

Developing of personalized therapies for Triple Negative Breast Cancer (TNBC) requires a more detailed knowledge of its biology and a correct stratification of molecular subtypes. Androgen Receptor (AR) is expressed in a large part of TNBCs but its prognostic role in this Breast Cancer (BC) subtype is highly debated. In this study, we analyzed AR expression in a series of 238 TNBCs and correlated its expression with clinical-pathological features, survival, and metabolic profile. We showed a consistent association between AR expression and a better prognosis of TNBC patients, while its downregulation appeared strongly associated with diabetic disease. Since a recent prospective study reported a lower BC risk in diabetic women treated with drugs able to reduce circulating levels of glucose compared with non-diabetic woman, and in vitro studies showed that AR level are regulated directly by hyperglycemia, we speculate on the perspective of new integrated therapies for TNBC.

Original languageEnglish
Pages (from-to)3530-3539
Number of pages10
JournalAmerican Journal of Translational Research
Volume8
Issue number8
Publication statusPublished - 2016

Keywords

  • Androgen receptor
  • Diabetes
  • Triple negative breast cancers

ASJC Scopus subject areas

  • Medicine(all)
  • Cancer Research
  • Clinical Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Downregulation of androgen receptor is strongly associated with diabetes in triple negative breast cancer patients'. Together they form a unique fingerprint.

  • Cite this